Key Highlights
- Veeva Systems stock rocketed 20% to $294.54, marking the company’s strongest single-day performance in its history
- Second quarter fiscal 2027 revenue reached $928 million, representing 18% annual growth and surpassing the $905 million analyst consensus
- Adjusted earnings per share of $2.35 exceeded expectations of $2.22; annual EPS outlook increased to $9.21
- Subscription-based revenue climbed 16% to $766.8 million; non-GAAP operating margin remained above 44%
- Major pharmaceutical companies Eli Lilly and Biogen adopted Vault CRM, expanding the platform’s reach to 12 of the top 20 biopharma organizations
Shares of Veeva Systems experienced their strongest rally in company history on Thursday, skyrocketing 20% to reach $294.54. The dramatic surge followed the life sciences cloud technology provider’s fiscal Q2 2027 report, which exceeded analyst projections across all major financial indicators.
The company reported quarterly revenue of $928 million, reflecting an 18% increase compared to the same period last year and outpacing Wall Street’s forecast of $905 million. Adjusted earnings per share reached $2.35, comfortably beating the analyst estimate of $2.22.
Company leadership increased their full-year fiscal 2027 revenue projection to a range of $3.68-$3.69 billion, surpassing the previous analyst consensus of approximately $3.65 billion. The adjusted EPS outlook for the full year was also boosted to $9.21 from the earlier guidance of $9.05.
Subscription revenue, which represents the most critical metric for Veeva’s business model, expanded 16% year-over-year to reach $766.8 million. The company’s non-GAAP operating margins remained robust above 44%, demonstrating that revenue expansion is being achieved while maintaining strong profitability.
Chief Executive Officer Peter Gassner highlighted that “Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly,” further noting that artificial intelligence is “opening up the next big chapter for Veeva and life sciences.”
The quarter saw two additional major pharmaceutical players from the industry’s top 20, Eli Lilly and Biogen, select Vault CRM as their platform of choice. This milestone brings the total number of top-20 biopharma companies utilizing the platform to 12.
Following the earnings announcement, approximately 20 Wall Street analyst firms increased their price targets on Veeva shares.
Wall Street Response
Barclays analyst Saket Kalia increased his price target to $315 from $275 while maintaining an Overweight rating. He highlighted the subscription revenue acceleration as a particularly encouraging indicator of sustained growth momentum.
Piper Sandler launched coverage with an Overweight rating and a $295 price target. Guggenheim boosted its target to $310 from $276, maintaining a Buy rating, and described Veeva as “indispensable for its customers.”
Morgan Stanley analyst Craig Hettenbach raised his price target to $275 from $215. He identified the company’s upcoming investor day scheduled for November 5 as the next important catalyst, characterizing it as “a referendum on the company’s AI strategy.”
Even analysts who have been more cautious showed renewed optimism. Canaccord increased its target to $260 from $220 while maintaining a Hold rating, describing the quarterly performance as one of the “cleanest” reports in recent memory.
Market Environment
Veeva’s rally occurred alongside broader strength in enterprise software stocks. Salesforce surged more than 20% on the same trading session after reporting better-than-expected Q2 results and announcing an expanded collaboration with Anthropic. ServiceNow and Datadog also recorded significant gains.
The technology sector received a boost from Nvidia’s earnings report earlier in the week, which appeared to renew investor confidence in tech and software equities. The Nasdaq Composite advanced 1.1% while the S&P 500 gained 0.5% on Thursday.
Veeva ranked as the second-strongest performer in the S&P 500 index for the day, trailing only Salesforce.
Shares opened at $239.87 in pre-market activity and traded at $264 before continuing their ascent throughout the regular trading session.
The company’s annual investor day on November 5 represents the next significant event on the calendar, where executive leadership is anticipated to provide comprehensive details regarding its artificial intelligence roadmap.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
